Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patricio Barros-Núñez is active.

Publication


Featured researches published by Patricio Barros-Núñez.


Nature Genetics | 2011

Mutations in CEP57 cause mosaic variegated aneuploidy syndrome

Katie Snape; Sandra Hanks; Elise Ruark; Patricio Barros-Núñez; Anna Elliott; Anne Murray; Andrew H Lane; Nora Shannon; Patrick Callier; David Chitayat; Jill Clayton-Smith; David Fitzpatrick; David Gisselsson; Sébastien Jacquemont; Keiko Asakura-Hay; Mark Micale; John Tolmie; Peter D. Turnpenny; Michael Wright; Jenny Douglas; Nazneen Rahman

Using exome sequencing and a variant prioritization strategy that focuses on loss-of-function variants, we identified biallelic, loss-of-function CEP57 mutations as a cause of constitutional mosaic aneuploidies. CEP57 is a centrosomal protein and is involved in nucleating and stabilizing microtubules. Our findings indicate that these and/or additional functions of CEP57 are crucial for maintaining correct chromosomal number during cell division.


Human Genetics | 1996

Recessive Schwartz-Jampel syndrome (SJS): confirmation of linkage to chromosome 1p, evidence of genetic homogeneity and reduction of the SJS locus to a 3-cM interval

Bertrand Fontaine; Sophie Nicole; Haluk Topaloglu; C. Ben Hamida; Peter Beighton; Frank Spaans; José María Cantú; Salim Bakouri; Norma B. Romero; K. Ricker; Patricio Barros-Núñez; Gérard Ponsot; M. Ben Hamida; Jean Weissenbach; F. Hentati; Frank Lehmann-Horn

Abstract Schwartz-Jampel syndrome (SJS), or chondrodystrophic myotonia, is a rare autosomal recessive disorder characterized by generalized myotonia resulting in a particular, recognizable facies and osteoarticular abnormalities. Some of us have recently shown genetic linkage of SJS to a locus on 1p34–p36.1 in five families. Here, we show by homozygosity mapping and segregation analysis that eight new families are most likely linked to the SJS locus on chromosome 1, confirming the localization of SJS to chromosome 1p and suggesting genetic homogeneity. Recombination events reduced the SJS locus from a genetic interval of 8 to 3 cM, which should facilitate the identification of the SJS gene. Low clinical variability was observed between the studied families, except for osteoarticular abnormalities. Since the severity and the location of osteoarticular abnormalities varied from one individual to another, even in the same families, other factors than the SJS gene itself, genetic or epigenetic, might contribute to the phenotype.


Human Biology | 2008

MDR1 C3435T Polymorphism in Mexican Children with Acute Lymphoblastic Leukemia and in Healthy Individuals

Evelia Leal-Ugarte; Melva Gutiérrez-Angulo; Nelly M. Macías-Gómez; Valeria Peralta-Leal; Jorge Durán-González; María de la Luz Ayala-Madrigal; Miriam Partida-Pérez; Patricio Barros-Núñez; Dinorah Ruiz-Díaz; José Moreno-Ortiz; Jorge Peregrina-Sandoval; Juan Pablo Meza-Espinoza

Abstract To determine the influence of the MDR1 C3435T polymorphism on the development of childhood acute lymphoblastic leukemia (ALL), we studied 107 children with ALL and 111 healthy subjects. All subjects were genotyped for the C3435T polymorphism using the polymerase chain reaction–restriction fragment length polymorphism method. The genotype frequencies in the patients were 17% homozygous CC, 61% heterozygous CT, and 22% homozygous TT; in healthy individuals the genotype frequencies were 14% CC, 53% CT, and 33% TT. In patients with ALL the allele frequencies were 0.47 for the C allele and 0.53 for the T allele; in the healthy group these allele frequencies were 0.40 and 0.60 for the C and T alleles, respectively. No significant differences in allele frequency (p > 0.176) and genotype frequency (p > 0.255) were detected between the two groups. These findings suggest that the CT or TT genotype does not increase the risk for childhood ALL in Mexican patients. On the other hand, significant differences in allele frequencies were detected in the comparison of Mexican healthy subjects with other populations. Whether these differences are fortuitous or related to diverse genetic backgrounds remains to be elucidated.


Archives of Medical Research | 2010

Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients.

Mónica Alejandra Rosales-Reynoso; Alejandra Berenice Ochoa-Hernández; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suárez; Rogelio Troyo-Sanromán; Patricio Barros-Núñez

BACKGROUND AND AIMS Although sporadic cases of cancer in patients with fragile X syndrome (FXS) have been reported, extensive studies carried out in Denmark and Finland concluded that cancer incidence in these patients is lower than in the general population. On the other hand, the FMR1 protein, which is involved in the translation process, is absent in FXS patients. Hence, it is reasonable to assume that these patients exhibit an abnormal expression of some proteins involved in regulating tumor suppressor genes and/or oncogenes, thus explaining its decreased cancer frequency. We undertook this study to analyze the expression of oncogenes and tumor suppressor genes in fragile X syndrome patients. METHODS Molecular analysis of the FMR1 gene was achieved in 10 male patients and controls. Total RNA from peripheral blood was used to evaluate expression of oncogenes and tumor suppressor genes included in a 10,000 gene microarray library. Quantitative real-time PCR was utilized to confirm genes with differential expression. RESULTS Among 27 genes showing increased expression in FXS patients, only eight genes exhibited upregulation in at least 50% of them. Among these, ARMCX2 and PPP2R5C genes are tumor suppressor related. Likewise, 23/65 genes showed decreased expression in >50% of patients. Among them, WNT7A gene is a ligand of the beta-catenin pathway, which is widely related to oncogenic processes. Decreased expression of WNT7A was confirmed by quantitative RT-PCR. Expression of c-Myc, c-Jun, cyclin-D and PPARdelta genes, as target of the beta-catenin pathway, was moderately reduced in FXS patients. CONCLUSIONS Results suggest that this diminished expression of the WNT7A gene may be related to a supposed protection of FXS patients to develop cancer.


Clinical Imaging | 2003

Femoral–facial syndrome with malformations in the central nervous system

Evelia Leal; Nelly Margarita Macías-Gómez; Lisa Rodrı́guez; F.Miguel Mercado; Patricio Barros-Núñez

The femoral hypoplasia-unusual facies syndrome (FFS) is a very rare association of femoral and facial abnormalities. Maternal diabetes mellitus has been mainly involved as the causal agent. We report the second case of FFS with anomalies in the central nervous system (CNS) including corticosubcortical atrophy, colpocephaly, partial agenesis of corpus callosum, hypoplasia of the falx cerebri and absent septum pellucidum. The psychomotor development has been normal. We propose that the CNS defects observed in these patients are part of the spectrum of abnormalities in the FFS.


BMC Cancer | 2012

Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation

Alejandra Berenice Ochoa-Hernández; Moisés Ramos-Solano; Ivan D Meza-Canales; Beatriz García-Castro; Mónica Alejandra Rosales-Reynoso; Judith A Rosales-Aviña; Esperanza Barrera-Chairez; Pablo Cesar Ortiz-Lazareno; Georgina Hernández-Flores; Alejandro Bravo-Cuellar; Luis Felipe Jave-Suárez; Patricio Barros-Núñez; Adriana Aguilar-Lemarroy

BackgroundWNT7a, a member of the Wnt ligand family implicated in several developmental processes, has also been reported to be dysregulated in some types of tumors; however, its function and implication in oncogenesis is poorly understood. Moreover, the expression of this gene and the role that it plays in the biology of blood cells remains unclear. In addition to determining the expression of the WNT7A gene in blood cells, in leukemia-derived cell lines, and in samples of patients with leukemia, the aim of this study was to seek the effect of this gene in proliferation.MethodsWe analyzed peripheral blood mononuclear cells, sorted CD3 and CD19 cells, four leukemia-derived cell lines, and blood samples from 14 patients with Acute lymphoblastic leukemia (ALL), and 19 clinically healthy subjects. Reverse transcription followed by quantitative Real-time Polymerase chain reaction (qRT-PCR) analysis were performed to determine relative WNT7A expression. Restoration of WNT7a was done employing a lentiviral system and by using a recombinant human protein. Cell proliferation was measured by addition of WST-1 to cell cultures.ResultsWNT7a is mainly produced by CD3 T-lymphocytes, its expression decreases upon activation, and it is severely reduced in leukemia-derived cell lines, as well as in the blood samples of patients with ALL when compared with healthy controls (p ≤0.001). By restoring WNT7A expression in leukemia-derived cells, we were able to demonstrate that WNT7a inhibits cell growth. A similar effect was observed when a recombinant human WNT7a protein was used. Interestingly, restoration of WNT7A expression in Jurkat cells did not activate the canonical Wnt/β-catenin pathway.ConclusionsTo our knowledge, this is the first report evidencing quantitatively decreased WNT7A levels in leukemia-derived cells and that WNT7A restoration in T-lymphocytes inhibits cell proliferation. In addition, our results also support the possible function of WNT7A as a tumor suppressor gene as well as a therapeutic tool.


Cancer Cell International | 2011

MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines

Susana del Toro-Arreola; Naela Arreygue-Garcia; Adriana Aguilar-Lemarroy; Angel Cid-Arregui; Miriam Jimenez-Perez; Jesse Haramati; Patricio Barros-Núñez; Oscar Gonzalez-Ramella; Alicia del Toro-Arreola; Pablo Cesar Ortiz-Lazareno; Georgina Hernández-Flores; Alejandro Bravo-Cuellar; Adrian Daneri-Navarro; Luis Felipe Jave-Suárez

BackgroundNatural killer (NK) cells are an important resource of the innate immune system directly involved in the spontaneous recognition and lysis of virus-infected and tumor cells. An exquisite balance of inhibitory and activating receptors tightly controls the NK cell activity. At present, one of the best-characterized activating receptors is NKG2D, which promotes the NK-mediated lysis of target cells by binding to a family of cell surface ligands encoded by the MHC class I chain-related (MIC) genes, among others. The goal of this study was to describe the expression pattern of MICA and MICB at the molecular and cellular levels in human cervical cancer cell lines infected or not with human papillomavirus, as well as in a non-tumorigenic keratinocyte cell line.ResultsHere we show that MICA and MICB exhibit differential expression patterns among HPV-infected (SiHa and HeLa) and non-infected cell lines (C33-A, a tumor cell line, and HaCaT, an immortalized keratinocyte cell line). Cell surface expression of MICA was higher than cell surface expression of MICB in the HPV-positive cell lines; in contrast, HPV-negative cells expressed lower levels of MICA. Interestingly, the MICA levels observed in C33-A cells were overcome by significantly higher MICB expression. Also, all cell lines released higher amounts of soluble MICB than of soluble MICA into the cell culture supernatant, although this was most pronounced in C33-A cells. Additionally, Real-Time PCR analysis demonstrated that MICA was strongly upregulated after genotoxic stress.ConclusionsThis study provides evidence that even when MICA and MICB share a high degree of homology at both genomic and protein levels, differential regulation of their expression and cell surface appearance might be occurring in cervical cancer-derived cells.


Pediatric and Developmental Pathology | 2005

Hamartoma involving the pseudarthrosis site in patients with neurofibromatosis type 1.

Rocı́o P. Mariaud-Schmidt; Sergio Rosales-Quintana; Emilio Bitar; Daniel Fajardo; Gilberto Chiapa-Robles; Amado González-Mendoza; Patricio Barros-Núñez

Congenital pseudarthrosis is a rare disease with variable clinical effects. The disease remains 1 of the most controversial pediatric entities in terms of etiopathogenesis, therapy, and prognosis. Between 0.5% and 2.2% of patients with neurofibromatosis demonstrate pseudarthrosis in any of the long bones. The exact origin of the lesion is even unclear; although several attempts have been made to determine the type of tissue involving the pseudarthrosis site, only fibrous tissue has been documented in different reports. We present 2 unrelated Mexican patients (male and female) with familial neurofibromatosis and congenital pseudarthrosis of the tibia and fibula. Histochemical and immunostain studies after surgical resection of the affected ends from the pseudarthrosis site of both patients showed a picture compatible with hamartoma. This is the first time when histologic evidence of hamartomatous tissue involving the pseudarthrosis site is presented.


American Journal of Medical Genetics Part A | 2004

Diastrophic dysplasia and atelosteogenesis type II as expression of compound heterozygosis: First report of a Mexican patient and genotype–phenotype correlation

Nelly Margarita Macías-Gómez; André Mégarbané; Evelia Leal‐Ugarte; Lisa Ximena Rodríguez-Rojas; Patricio Barros-Núñez

The osteochondrodysplasias represent a heterogeneous group of cartilage and bone diseases. Among these, achondrogenesis 1B, atelosteogenesis type II, diastrophic dysplasia, and autosomal recessive multiple epiphyseal dysplasia are caused by mutations in the solute carrier family 26 (sulfate transporter), member 2 gene (SLC26A2). This group of osteochondrodysplasias shows a continuous spectrum of clinical variability and shares many features in common. Usually, it is difficult to distinguish clinically among these patients. To date, several efforts have been made to correlate mutations in the SLC26A2 gene with phenotypic severity in the patients. We report on a Mexican girl with diastrophic dysplasia presenting some unusual clinical and radiographic features that are usually observed in atelosteogenesis type II. Molecular analysis of the SLC26A2 gene in this patient showed compound heterozygosity for the R178X and R279W mutations. In this patient, the combination of a mild and a severe mutation has apparently led to an intermediate or transitional clinical picture, showing an apparent genotype–phenotype correlation.


Clinical Imaging | 2002

Melorheostosis: Unusual presentation in a girl

Rocı́o P. Mariaud-Schmidt; Wadih Emilio Bitar; Francisco Pérez-Lamero; Patricio Barros-Núñez

Melorheostosis is a rare bone disease of unknown etiology. It is characterized by tense and erythematous skin, contractures and shortening of the affected limbs. Radiographs reveal hyperostosis in long bones resembling melting wax, and spotty or patchy endostic deposits in short bones. An 11-year-old girl showed, since birth, contractural deformities in the right hand without bone abnormalities. At the age of 12 months, she complained of soft tissue tightness in the right buttock. At 3 years, limitation of flexion and extension of the right knee was evident. Radiographs revealed findings typical of melorheostosis.

Collaboration


Dive into the Patricio Barros-Núñez's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Clara Ibet Juárez-Vázquez

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Horacio Rivera

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adriana Aguilar-Lemarroy

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

José María Cantú

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Luis Felipe Jave-Suárez

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar

Pavel Romero-Espinoza

Mexican Social Security Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge